Skip to main content

Table 2 All Grade AEs in ≥10% of patients regardless of attribution to navoximod

From: Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

  Navoximod 50 mg BID (n = 1) Navoximod 100 mg BID (n = 3) Navoximod 200 mg BID (n = 3) Navoximod 400 mg BID (n = 3) Navoximod 600 mg BID (n = 3) Navoximod 800 mg BID (n = 6) All Patients 21/28 day schedule (N = 19) Navoximod continuous schedule 600 mg BID (n = 3) All Patients (N = 22)
Any adverse event 1 (100%) 3 (100%) 3 (100%) 3 (100%) 3 (100%) 6 (100%) 19 (100%) 3 (100%) 22 (100%)
Fatigue 1 (100%) 2 (67%) 3 (100%) 1 (33%) 1 (33%) 3 (50%) 11 (58%) 2 (67%) 13 (59%)
Cough 1 (100%) 3 (100%) 1 (33%) 4 (67%) 9 (47%) 9 (40%)
Decreased appetite 1 (100%) 2 (67%) 3 (100%) 3 (50%) 9 (47%) 9 (40%)
Pruritus 2 (67%) 2 (67%) 1 (33%) 2 (67%) 1 (17%) 8 (42%) 1 (33%) 9 (40%)
Nausea 1 (100%) 3 (100%) 1 (33%) 1 (33%) 2 (67%) 8 (42%) 8 (36%)
Vomiting 1 (33%) 1 (33%) 1 (33%) 1 (33%) 1 (17%) 5 (26%) 1 (33%) 6 (27%)
Anxiety 1 (100%) 1 (33%) 1 (33%) 1 (17%) 4 (21%) 4 (18%)
AST increased 1 (33%) 1 (33%) 2 (33%) 4 (21%) 4 (18%)
Constipation 2 (67%) 2 (33%) 4 (21%) 4 (18%)
Dyspepsia 2 (67%) 2 (67%) 4 (21%) 4 (18%)
Dyspnea 1 (100%) 1 (33%) 2 (33%) 4 (21%) 4 (18%)
Wheezing 1 (100%) 1 (33%) 1 (33%) 1 (17%) 4 (21%) 4 (18%)
Rash terms a 1 (33%) 1 (33%) 1 (33%) 1 (33%) 4 (21%) 1 (33%) 5 (23%)
Abdominal pain 2 (67%) 1 (17%) 3 (16%) 1 (33%) 4 (18%)
Hypokalemia 1 (100%) 1 (33%) 1 (17%) 3 (16%) 1 (33%) 4 (18%)
Ascites 1 (33%) 1 (33%) 1 (17%) 3 (16%) 3 (14%)
Neoplasm progression 1 (33%) 1 (33%) 1 (33%) 3 (16%) 3 (14%)
Upper respiratory tract infection 1 (33%) 1 (33%) 1 (17%) 3 (16%) 3 (14%)
Dry mouth 2 (67%) 2 (11%) 1 (33%) 3 (14%)
  1. aRash terms = rash and rash maculopapular